Stephen Mackinnon

14.8k citations
196 papers · 9.8k · 2 hit papers · h-index 51

Impact in

  • Hematology top 0.05%
    • Hematopoietic Stem Cell Transplantation
    • Acute Myeloid Leukemia Research
  • Immunology top 0.5%
    • Immune Cell Function and Interaction
    • T-cell and B-cell Immunology

Papers in

  • Hematology 118
    • Hematopoietic Stem Cell Transplantation 90
    • Chronic Myeloid Leukemia Treatments 34
  • Immunology 60
    • Immune Cell Function and Interaction 35
    • T-cell and B-cell Immunology 31
Co-authors
Karl S. Peggs (66 shared papers)Kirsty Thomson (47 shared papers)David C. Linch (32 shared papers)Anthony H. Goldstone (27 shared papers)Stephanie Verfuerth (20 shared papers)Farid Boulad (6 shared papers)Hugo Castro‐Malaspina (6 shared papers)Emma Morris (28 shared papers)
Journals
Blood (58 papers)British Journal of Haematology (23 papers)Bone Marrow Transplantation (21 papers)Biology of Blood and Marrow Transplantation (13 papers)Journal of Clinical Oncology (7 papers)
Partner nations
United KingdomUnited StatesSpain

In The Last Decade

Stephen Mackinnon

193 papers receiving 9.6k citations

Stephen Mackinnon's Hit Papers

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease 1995 · 601 citations
6010+10+21Years since publication250500750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 1995 Blood
  2. 1994 New England Journal of Medicine

Peers

Stephen Mackinnon
Comparison fields: 5 of 118
  • Hematology 5.0k
  • Immunology 3.6k
  • Transplantation 392
  • Oncology 3.2k
  • Genetics 1.1k
Replace Yasuo Morishima with:
Yasuo Morishima Japan
Nancy A. Kernan United States
Jan Storek Canada
Hildegard Greinix Austria
Peter Bader Germany
Robert A. Krance United States
George E. Sale United States
Chaim Brautbar Israel
Hugo Castro‐Malaspina United States
Peter A. McSweeney United States
Stephen Mackinnon relative to Yasuo Morishima Japan Yasuo Morishima's profile →
Citations per field
00.5×1.5×
Yasuo Morishima · 1×
Citations per year

Countries citing papers authored by Stephen Mackinnon

Since Specialization
Citations

This map shows the geographic impact of Stephen Mackinnon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Mackinnon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Mackinnon more than expected).

Fields of papers citing papers by Stephen Mackinnon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Mackinnon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Mackinnon. The network helps show where Stephen Mackinnon may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen Mackinnon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen Mackinnon Line = papers co-authored together Stephen Mackinnon links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 196 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
New England Journal of Medicine ·Esperanza B. Papadopoulos, Marc Ladanyi, David Emanuel, Stephen Mackinnon, Farid Boulad, Matthew Carabasi, Hugo Castro‐Malaspina, Barrett H. Childs, Alfred P. Gillio, Trudy N. Small, James W. Young, Nancy A. Kernan, Richard J. O’Reilly
Hit paper breakdown →		1994811
2
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease
Blood ·Stephen Mackinnon, EB Papadopoulos, MH Carabasi, Lilian Reich, NH Collins, Farid Boulad, Hugo Castro‐Malaspina, BH Childs, AP Gillio, NA Kernan
Hit paper breakdown →		1995601
3
Comparison of Immune Reconstitution After Unrelated and Related T-Cell–Depleted Bone Marrow Transplantation: Effect of Patient Age and Donor Leukocyte Infusions
Blood ·TN Small, Esperanza B. Papadopoulos, Farid Boulad, P Black, Hugo Castro‐Malaspina, BH Childs, N H Collins, AP Gillio, Diane George, Ann A. Jakubowski, Glenn Heller, Melissa Fazzari, Nancy A. Kernan, Stephen Mackinnon, Paul Szabolcs, James W. Young, R.J. O’Reilly
1999388
4
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
The Lancet ·Karl S. Peggs, Stephanie Verfuerth, Arnold Pizzey, Naeem Khan, Malcolm Guiver, Paul Moss, Stephen Mackinnon
2003371
5
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
Blood ·Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra, Panagiotis Kottaridis, Karl S. Peggs, Peter O’Gorman, Ronjon Chakraverty, Timothy Marshall, Husam Osman, Premini Mahendra, Charles Craddock, Herman Waldmann, G Hale, Chris Fegan, Kwee Yong, Anthony H. Goldstone, David C. Linch, Donald Milligan
2002300
6
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
Blood ·Stephen Robinson, Anthony H. Goldstone, Stephen Mackinnon, Angelo Michele Carella, Nigel H. Russell, Carmen Ruiz de Elvira, Goli Taghipour, Norbert Schmitz
2002289
7
Specific human cellular immunity to bcr-abl oncogene-derived peptides
Blood ·Monica Bocchia, Tatyana Korontsvit, Qin Xu, Stephen Mackinnon, Shang‐You Yang, Alessandro Sette, DA Scheinberg
1996231
8
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
Blood ·Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Gordon Cook, Graeme Smith, Anne Parker, Steve Schey, Rajesh Chopra, Christopher Hatton, Jane Tighe, Anne Hunter, Karl S. Peggs, David C. Linch, Anthony P. Goldstone, Stephen Mackinnon
2004222
9
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation ·Joseph H. Antin, Richard Childs, Alexandra H. Filipovich, Sergio Giralt, Stephen Mackinnon, Thomas R. Spitzer, Daniel J. Weisdorf
2001197
10
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
Blood ·José Antonio Pérez‐Simón, Panagiotis Kottaridis, Rodrigo Martino, Charles Craddock, Dolores Caballero, Raj Chopra, J Garcı́a-Conde, Don Milligan, Stephen Schey, Álvaro Urbano-Ispizúa, Anne Parker, Ángel León, Kwee Yong, Ana Sureda, Ann Hunter, Jordi Sierra, Anthony H. Goldstone, David C. Linch, Jesús F. San Miguel, Stephen Mackinnon
2002190
11
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
The Lancet ·Karl S. Peggs, Ann Hunter, Rajesh Chopra, Anne Parker, Premini Mahendra, Donald Milligan, Charles Craddock, Ruth Pettengell, Ahmet Doǧan, Kirsty Thomson, Emma Morris, G Hale, Herman Waldmann, Anthony H. Goldstone, David C. Linch, Stephen Mackinnon
2005185
12
Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation
Clinical Infectious Diseases ·Karl S. Peggs, Kirsty Thomson, Edward Samuel, Gemma Dyer, Julie Armoogum, Ronjon Chakraverty, K. H. Pang, Stephen Mackinnon, Mark W. Lowdell
2010178
13
Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia
Journal of Clinical Oncology ·Sudhir Tauro, Charles Craddock, Karl S. Peggs, Gulnaz Begum, Premini Mahendra, Gordon Cook, Judith Marsh, Donald Milligan, Anthony P. Goldstone, Ann Hunter, Asim Khwaja, Raj Chopra, Timothy J. Littlewood, Andrew Peniket, Anne Parker, Graham Jackson, G Hale, Mark Cook, Nigel H. Russell, Stephen Mackinnon
2005175
14
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
Blood ·Karl S. Peggs, Kirsty Thomson, Daniel P. Hart, Johanne Geary, Emma Morris, Kwee Yong, Anthony H. Goldstone, David C. Linch, Stephen Mackinnon
2003162
15
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
Blood ·Emma Morris, Peppy Rebello, Kirsty Thomson, Karl S. Peggs, Charalampia Kyriakou, Anthony H. Goldstone, Stephen Mackinnon, G Hale
2003160
16
The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation
Blood ·Andrea Knight, J. Alejandro Madrigal, Sarah Grace, Janani Sivakumaran, Panagiotis Kottaridis, Stephen Mackinnon, Paul Travers, Mark W. Lowdell
2010159
17
T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease
Blood ·Esperanza B. Papadopoulos, Matthew Carabasi, Hugo Castro‐Malaspina, Barrett H. Childs, Stephen Mackinnon, Farid Boulad, Alfred P. Gillio, Nancy A. Kernan, Trudy N. Small, Paul Szabolcs, Joanne Taylor, Joachim Yahalom, Nancy Collins, Sharon A. Bleau, P Black, Glenn Heller, Richard J. O' Reilly, James W. Young
1998157
18
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation.
PubMed ·É. Kaminski, Jill Hows, Stephen Man, Paul Brookes, Stephen Mackinnon, Timothy P. Hughes, O. Avakian, J. M. Goldman, J. R. Batchelor
1989138
19
Minimal residual disease is more common in patients who have mixed T- cell chimerism after bone marrow transplantation for chronic myelogenous leukemia
Blood ·Stephen Mackinnon, L Barnett, Glenn Heller, RJ O’Reilly
1994137
20
Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma
Journal of Clinical Oncology ·Kirsty Thomson, Emma Morris, Adrian Bloor, Gordon Cook, Don Milligan, Anne Parker, Fiona Clark, Lynny Yung, David C. Linch, Ronjon Chakraverty, Karl S. Peggs, Stephen Mackinnon
2008119

About Stephen Mackinnon

Stephen Mackinnon is a scholar working on Hematology, Immunology, Epidemiology, Oncology and Genetics, having authored 196 papers that have together received 9.8k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (90 papers), Cytomegalovirus and herpesvirus research (46 papers), Immune Cell Function and Interaction (35 papers), Chronic Myeloid Leukemia Treatments (34 papers), Lymphoma Diagnosis and Treatment (32 papers), T-cell and B-cell Immunology (31 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Viral-associated cancers and disorders (19 papers). The work is most often cited by research in Hematology (5.0k citations), Immunology (3.6k citations), Transplantation (392 citations), Oncology (3.2k citations) and Genetics (1.1k citations). Stephen Mackinnon has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Karl S. Peggs, Kirsty Thomson, David C. Linch, Anthony H. Goldstone, Stephanie Verfuerth, Farid Boulad, Hugo Castro‐Malaspina, Emma Morris, Ronjon Chakraverty and Panagiotis Kottaridis. Their work appears in journals such as Blood, British Journal of Haematology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasuo MorishimaBreakdown of academic impact, for papers by Nancy A. KernanBreakdown of academic impact, for papers by Jan StorekBreakdown of academic impact, for papers by Hildegard GreinixBreakdown of academic impact, for papers by Peter BaderBreakdown of academic impact, for papers by Robert A. KranceBreakdown of academic impact, for papers by George E. SaleBreakdown of academic impact, for papers by Chaim BrautbarBreakdown of academic impact, for papers by Hugo Castro‐MalaspinaBreakdown of academic impact, for papers by Peter A. McSweeney